Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity

Abstract Background Tumor-targeted nanoparticles hold great promise as new tools for therapy of liquid cancers. Furthermore, the therapeutic efficacy can be improved by enhancing cancer cellular internalization. Methods In this study, we developed a humanized bispecific antibody (BsAbs: CD20 Ab-mPEG scFv) which retains clinical anti-CD20 whole (Ofatumumab) and is fused with an anti-mPEG single chain (scFv) that target systemic tumor cells. This combination achieves function simultaneously “grabs” Lipo-Dox® (PEGylated liposomal doxorubicin, PLD) to enhance internalization anticancer activity PLD. Results We successfully constructed scFv proved CD20-expressing Raji cells grab PEGylated DiD increasing ability up 60% in 24 h. further showed PLD led ninefold increase cytotoxicity (LC 50 : 0.38 nM) compared Ab-DNS (lC 3.45 vitro. Importantly, had greater anti-liquid ( P = 0.0005) Raji-bearing mice than Conclusion Our results indicate “double-attack” strategy using retain targeting first attack ) confer tumor-selectivity second improve tumors.